Wells Fargo & Company Edgewise Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $507 Billion
- Q3 2025
A detailed history of Wells Fargo & Company transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 42,196 shares of EWTX stock, worth $959,959. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,196
Previous 38,384
9.93%
Holding current value
$959,959
Previous $503,000
35.98%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding EWTX
# of Institutions
186Shares Held
112MCall Options Held
188KPut Options Held
121K-
Orbimed Advisors LLC San Diego, CA15.5MShares$353 Million8.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.4MShares$237 Million2.9% of portfolio
-
Baker Bros. Advisors LP New York, NY7.31MShares$166 Million0.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.17MShares$140 Million3.22% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$137 Million0.0% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.44B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...